The aims of this study were to (i) describe the typology of patients admitted to the day hospital for cognitive disorders of the Alzheimer's Disease Unit, Brescia, Italy, and (ii) describe the diagnostic, therapeutic and rehabilitative interventions carried out. Data are presented on the first 102 c
The introduction of 7-day platelets: A university hospital experience
β Scribed by Shauna N. Hay; Caroline C. Immel; Laura S. McClannan; Mark E. Brecher
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 115 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Introduction: Recently, the FDA approved the Post Approval Surveillance Study of Platelet Outcomes, Release Tested protocol which allows participating institutions to utilize 7 day platelets following guidelines. As one of the first hospitals to implement a 7βday protocol, we reviewed our hospital experience with 7βday Gambro apheresis platelets to determine the impact on inventory. Methods: A review of apheresis platelet transfusions and outdate records was performed. Data were collected prospectively from March to August 2006. This data were compared with a retrospective review for the same time period in 2005. Results: For the 1,503 platelets transfused from MarchβAugust 2005, the mean day of issue was 3.44 (SD = 1.060). During the same time period of 2006, 1,688 platelets were transfused with a mean day of issue of 4.02 (SD = 1.083). This difference was statistically significant (P < 0.001). The outdate rate dropped from 2.9% (44/1,547) to 1.3% (22/1,710, P < 0.001). During the study period, βΌ59.7% of the platelets were 7βday platelets. Discussion: Over the 6βmonth period, we noted a decrease in outdates from 2.9% to 1.3%. There was a shift toward older platelets (from a mean of day 3.4 to day 4). During the study period, 139 platelets were transfused on days 6 or 7 of storage. Overall, the implementation of 7βday platelets in a university hospital setting was easily accomplished and has resulted in benefits to our institution by decreasing our outdate rate and to our patients by providing an additional 139 days 6 and 7 apheresis platelets with a potential cost savings of $78,952 (over the 6βmonth study). J. Clin. Apheresis, 2007. Β© 2007 WileyβLiss, Inc.
π SIMILAR VOLUMES
We evaluated the treatment experiences with thyroid carcinoma at a private, a Veterans Administration, and a University hospital to determine the frequency, treatment, and outcome of patients with this uncommon malignant tumor. All 120 patients with thyroid carcinoma were identified through hospital